Rare Inc

DEFENSE PRODUCTION ACT TITLE III, COMMERCIAL PRODUCTION OF HEAVY RARE EARTH ELEMENTS FROM RECYCLED LAMP PHOSPHORS

DEFENSE PRODUCTION ACT (DPA) TITLE III - RECOVERY AND RECYCLING OF END OF LIFE NEFEB MAGNETS THROUGH RARE EARTH EXTRACTION

FEASIBILITY STUDY FOR MID-STREAM PROCESSING OF RARE EARTH MINERALS IN ANGOLA.

HARNESSING MARKETS TO SECURE A FUTURE FOR NEAR SHORE FISHERS

COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION - CURE RARE DISEASE (CRD) IS A NONPROFIT BIOTECHNOLOGY COMPANY DEDICATED TO THE DEVELOPMENT OF LIFE-SAVING GENE THERAPIES FOR PATIENTS, PRIMARILY PEDIATRIC, WHO ARE IMPACTED BY PROGRESSIVE, RARE GENETIC DISORDERS FOR WHICH THERE IS NO CURE. THE GENESIS OF CURE RARE DISEASE IS EXTREMELY PERSONAL – THE FOUNDER’S BROTHER, TERRY HORGAN, IS IMPACTED BY A RARE, NEUROMUSCULAR DISEASE THAT HAS NO TREATMENT. A NEW APPROACH TO TREAT THESE RARE AND ULTRA-RARE DISEASES IS NECESSARY AND THUS WAS BORN CRD. THROUGH A COLLABORATION OF THE NATION’S TOP SCIENTISTS AND CLINICIANS, CRD HAS DEVELOPED A FIRST-IN-HUMAN CRISPR (GENOME EDITING) BASED DRUG FOR TERRY AND IS DEVELOPING A BATTERY OF THERAPEUTICS FOR OVER 15 OTHER UNIQUE GENETIC MUTATIONS. TO EXPAND THE MISSION AND IMPACT ON THE LIVES OF RARE DISEASE PATIENTS, CRD ESTABLISHED A PHYSICAL LAB FOOTPRINT IN THE STATE OF CONNECTICUT. CRD ACQUIRED A PROMISING LAB SPACE AT 4 RESEARCH DRIVE IN WOODBRIDGE, CT (NEW HAVEN COUNTY) WHERE WE WILL RENOVATE AN EXISTING BUILDING TO BE FIT FOR RESEARCH AND DEVELOPMENT ACTIVITIES. CRD CURRENTLY FUNDS NUMEROUS SCIENTISTS AND OUR GOAL IS TO BRING THOSE SCIENTISTS IN HOUSE TO BE ABLE TO FOCUS MORE OF THEIR TIME AND ENERGIES ON OUR MISSION. THE BUILDING IS A 30,000SQFT FACILITY COMPRISED OF TWO LEVELS OF LAB SPACE. WE ARE REQUESTING SUPPORT TO RENOVATE THE BUILDING WHICH WILL INCLUDE BOTH EXTERIOR RENOVATIONS AS WELL AS INTERIOR RENOVATIONS. THE EXTERIOR RENOVATIONS WILL INCLUDE REFURBISHING THE PARKING LOT, REPAIRING AND CLEANING PORTIONS OF THE BUILDING WHICH HAVE FALLEN INTO DISREPAIR AND ENSURING ADA COMPLIANCE OF THE BUILDING. WE HAVE ENLISTED THE SUPPORT OF A LOCAL, WELL-RESPECTED ARCHITECTURAL FIRM, SVIGALS + PARTNERS, TO SUPPORT THE ARCHITECTURAL ANALYSIS AND DRAWINGS FOR THE BUILDING. THIS GROUP OFFERS POTENTIAL CONTRACTORS TO USE FOR RENOVATIONS. INTERIOR RENOVATIONS INCLUDES CONSTRUCTION FOR REVAMPING EXISTING LAB SPACE AND INSTALLATION OF NECESSARY COMPONENTS SUCH AS LAB BENCHES, VACUUM HOODS, EQUIPMENT FOR TISSUE CULTURES, EQUIPMENT FOR HOUSING AND RODENT ANIMAL MODELS. WE ANTICIPATE HIRING 4-10 RESEARCH PERSONNEL TO SUPPORT ONGOING OPERATIONS, ALL OF WHOM WILL BE YIELDED FROM NEW HAVEN COUNTY. RESEARCH PERSONNEL WILL FOCUS THEIR EFFORTS ON IDEATING AND GENERATING NOVEL THERAPEUTIC TECHNOLOGIES FOR THE AFOREMENTIONED PATIENTS. OF NOTE, SEVERAL OF OUR RARE DISEASE PATIENTS LIVE IN NEW HAVEN AND FAIRFIELD COUNTIES.

RAPID HIGHLY MULTI-PLEXED IMMUNO-PROFILING OF SOLID TUMORS BY SPECTRALEDGE IMAGING

SBIR PHASE II: BIOLOGICAL PRODUCTION OF PARAXANTHINE, A CAFFEINE REPLACEMENT -THE BROADER IMPACT OF THIS SMALL BUSINESS INNOVATION (SBIR) PHASE II PROJECT IS THE DEVELOPMENT OF A BIOMANUFACTURING PROCESS TO PRODUCE PARAXANTHINE FOR USE AS A CAFFEINE ALTERNATIVE IN BEVERAGES AND FOODS. FOR A LARGE PERCENTAGE OF THE POPULATION, CAFFEINE IS KNOWN TO HAVE NEGATIVE SIDE EFFECTS, INCLUDING ANXIETY, JITTERINESS, AND NEGATIVE EFFECTS ON SLEEP QUALITY. IN THE CASE OF ANXIETY, AN ESTIMATED 40MM AMERICANS SUFFER FROM AN ANXIETY DISORDER, AND THE CONSUMPTION OF CAFFEINE IN COFFEE, ENERGY DRINKS, AND OTHER BEVERAGES IS KNOWN TO EXACERBATE STRESS. PARAXANTHINE IS AN ACTIVE METABOLITE OF CAFFEINE THAT HAS SIMILAR STIMULATORY QUALITIES BUT WITH POTENTIALLY FEWER SIDE EFFECTS. ADDITIONALLY, PARAXANTHINE HAS A SHORTER HALF-LIFE (I.E., IT IS CLEARED FROM THE BODY FASTER) AS COMPARED TO CAFFEINE. THUS, PARAXANTHINE MAY PLAY A ROLE IN CONTRIBUTING TO IMPROVED SLEEP QUALITY AND MENTAL WELLNESS. THE PROPOSED PROJECT AIMS TO DEVELOP A COST-EFFICIENT, BIOLOGICAL METHOD TO MANUFACTURE PARAXANTHINE. PRODUCING PARAXANTHINE AT LOW COST IS CURRENTLY A SIGNIFICANT TECHNICAL CHALLENGE. THE COMPOUND IS ONLY FOUND NATURALLY IN SUBSTANTIAL QUANTITIES WITHIN THE HUMAN BODY AS THE RESULT OF CAFFEINE METABOLISM; IT IS NOT PRODUCED IN PLANTS IN ABOVE TRACE AMOUNTS. FURTHERMORE, SYNTHETIC METHODS TO PRODUCE PARAXANTHINE ARE COMPLEX AND RELATIVELY EXPENSIVE. THE RESEARCH GOALS OF THIS PHASE II PROJECT ARE TO DEVELOP AND OPTIMIZE A PROCESS USING AN ENGINEERING ENZYME TO FERMENTATIVELY PRODUCE PARAXANTHINE AT HIGH YIELDS AND WITH HIGH VOLUMETRIC PRODUCTIVITIES. THE APPROACH SEEKS TO EMPLOY REAL-TIME BIOREACTOR MONITORING, ENABLING RAPID ITERATION OF THE EXPERIMENTAL DESIGN-BUILD-TEST CYCLE. IF SUCCESSFUL, THIS TECHNOLOGY WILL NOT ONLY DELIVER AN EFFICIENT PARAXANTHINE PRODUCTION PROCESS, BUT IT ALSO ESTABLISHES A NOVEL, SCALABLE PLATFORM THAT CAN BE APPLIED TO IMPROVE UPON OTHER FOOD INGREDIENTS, PHARMACEUTICALS, AND INDUSTRIAL CHEMICALS. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.

DGP GRANT - CLIMATE CHANG ADAPTATION IN MPAS AND COASTAL COMMUNITIES

PREVENTING VASCULAR COMPLICATIONS IN TYPE 1 DIABETES: MUSCLE METABOLIC MONITORING

SBIR PHASE II: SUSTAINABLE RARE EARTH ELEMENT RECYCLING FROM NEODYMIUM MAGNETS

DEVELOPMENT OF HTS ASSAY AND SCREENING PARADIGM TO DISCOVER NEW KINASE INHIBITORS

ADAPTIVE IMAGING FOR PIONEERING MULTIPLEXED SPATIAL PROFILING OF TUMORS AND TISSUES FOR CANCER RESEARCH AND DIAGNOSIS - SUMMARY HISTOPATHOLOGY PLAYS A CENTRAL ROLE IN THE DIAGNOSIS AND STAGING OF CANCER BY ENSURING THAT INDIVIDUAL TREATMENT PLANS CORRECTLY ACCOUNT FOR TISSUE OF ORIGIN, TUMOR CELL STATE, AND IMMUNE STATUS. DESPITE ITS IMPORTANCE, HISTOPATHOLOGY HAS CHANGED LITTLE OVER THE PAST FIFTY YEARS: IN BOTH DIAGNOSTIC AND RESEARCH SETTINGS, MANUAL EXAMINATION OF HEMATOXYLIN AND EOSIN (H&E) STAINED SLIDES REMAINS THE NORM WITH ADDITIONAL INFORMATION PROVIDED IN SOME CASES BY IMMUNOHISTOCHEMISTRY (IHC). HOWEVER, TWO BREAKTHROUGHS ARE NOW IMPACTING IMAGE-BASED ANALYSIS OF TISSUES AND TUMORS: (I) METHODS THAT QUANTIFY 10-60 PROTEIN MARKERS IN TISSUE SECTIONS AT SUBCELLULAR RESOLUTION AND (II) APPROACHES TO MACHINE LEARNING/ARTIFICIAL INTELLIGENCE (ML/AI) ABLE TO INTERPRET DIGITAL IMAGES AT SCALE. THIS PROPOSAL FOCUSES ON COMBINING THESE ADVANCES IN A FUNDAMENTALLY NEW APPROACH TO ACQUIRING HIGHLY MULTIPLEXED TISSUE IMAGES FROM THE FORMALDEHYDE FIXED PARAFFIN EMBEDDED (FFPE) SPECIMENS THAT ARE THE MAINSTAY OF ALL PATHOLOGY WORKFLOWS AND THEN COMPUTING SPATIAL PROFILES. OUR PROPOSED ORION2 APPROACH WILL DRAMATICALLY EXTEND AN ORIONTM METHOD THAT WE RECENTLY COMMERCIALIZED; ORION IS ABLE TO COLLECT 18 TO 20 PLEX IMMUNOFLUORESCENCE DATA IN A SINGLE ROUND OF IMAGING FOLLOWED BY DIAGNOSTIC GRADE H&E IMAGING ON THE SAME SECTION (CYCLING ALLOWS FOR HIGHER PLEX ANALYSIS). ORION2 WILL IMPLEMENT AN “ATTENTION-BASED” APPROACH THAT FOCUSES IMAGE ACQUISITION ON THE MOST IMPORTANT OR INFORMATIVE REGIONS OF A SPECIMEN. THIS WILL BE ACCOMPLISHED BY FIRST SCANNING SPECIMENS AT RELATIVELY LOW MAGNIFICATION AND THEN USING AUTOMATED ALGORITHMS TO PRIORITIZE SPECIFIC TISSUE FEATURES FOR HIGH-RESOLUTION 2D AND 3D IMAGE ACQUISITION. THIS TYPE OF ADAPTIVE IMAGING RECAPITULATES THE WAY IN WHICH HISTOPATHOLOGISTS EXAMINE COMPLEX TISSUE SPECIMENS AT LOW AND HIGH POWER WHILE ADDING MOLECULAR DETAIL AND THE AUTOMATION POSSIBLE WITH DIGITAL IMAGING. THE ORION2 INSTRUMENT WILL MEET FDA REQUIREMENTS FOR WHOLE-SLIDE IMAGING (WSI) IN DIAGNOSIS AND WILL ACHIEVE THE SPATIAL POWER NEEDED TO RELIABLY IDENTIFY RECURRENT CELL POPULATIONS AND SPATIAL FEATURES OF TUMORS ASSOCIATED WITH DISEASE PROGRESSION OR DRUG RESPONSE. AIM 1 FOCUSES ON THE DEVELOPMENT OF AN INSTRUMENT WITH AUTOMATED CONTROL OVER TRANSMITTED AND FLUORESCENCE ILLUMINATION TO ALLOW SPEED OF DATA ACQUISITION AND INCREASED IMAGE RESOLUTION TO BE BALANCED AGAINST EACH OTHER TO VARYING DEGREE. AIM 2 INVOLVES THE DEVELOPMENT OF CLASSICAL AND MACHINE LEARNING ALGORITHMS ABLE TO USE LOW MAGNIFICATION SCANS TO PRIORITIZE SPECIFIC TISSUE FEATURES FOR IN-DEPTH ANALYSIS. AIM 3 LINKS THESE TWO DEVELOPMENTS IN AN INSTRUMENT THAT USES CLOSED-LOOP CONTROL TO COLLECT OPTIMIZED MID-PLEX MULTI- RESOLUTION IMAGES OF SOLID TUMORS WITH AN INITIAL FOCUS ON COMMON CANCER TYPES (BREAST, LUNG, AND COLORECTAL CANCERS) AND MOUSE MODELS OF THESE DISEASES. DRAWING ON OUR EXPERIENCE WITH ASSAY DEVELOPMENT, OPTICS, AND IN VITRO DIAGNOSTICS, ORION2 WILL SET A STANDARD FOR IMAGE QUALITY, EASE OF USE, REPEATABILITY, AND THROUGHPUT NOT ACHIEVED BY ANY EXISTING APPROACH AND WILL UNLOCK NEW MARKETS IN ACADEME, INDUSTRY AND MEDICINE.

DIRECT VISUALIZATION ASSAY FOR DETECTION OF B. BURGDORFERI IN EARLY LYME DISEASE

TESTING MALT1 INHIBITORS AS A TREATMENT FOR THE RARE PEDIATRIC INBORN ERROR OF IMMUNITY CARD11 GAIN OF FUNCTION - CARD11 GAIN OF FUNCTION (GOF) IS A RARE GENETIC DISORDER DUE TO INBORN VARIANTS IN THE CARD11 GENE THAT CONFER A BIOCHEMICAL GAIN OF FUNCTION. IN CHILDREN, THESE INBORN ERRORS CAUSE RECURRENT INFECTIONS, SEVERE AUTOIMMUNITY, ENLARGED LYMPH NODES AND SPLEEN, AND INCREASED RISKS OF LYMPHOMA. THERE IS CURRENTLY NO CURE FOR THIS DISEASE, AND PATIENTS ARE MANAGED WITH STEROIDS OR BONE MARROW TRANSPLANTATION. RAREFIED BIOSCIENCES IS DEVELOPING A PRECISELY TARGETED TREATMENT FOR CARD11 GOF. OUR PRELIMINARY DATA AND WORK FROM OUR CONSULTANT, COLLABORATOR, AND DISCOVERER OF CARD11 GOF, DR. ANDREW SNOW, SHOW THAT BLOCKADE OF MALT1, THE PROTEASE THAT WORKS IN COMPLEX WITH CARD11, COULD BE AN EFFECTIVE TREATMENT FOR CARD11 GOF. RAREFIED BIOSCIENCES IS A NEW STARTUP THAT ACQUIRED A SMALL-MOLECULE, ORALLY AVAILABLE MALT1 INHIBITOR FROM RHEOS MEDICINES, WHICH RAN OUT OF MONEY IN 2023. RAREFIED WAS FOUNDED BY THE PI (DR. BUTTE), AN INTERNATIONAL LEADER IN PEDIATRIC IMMUNOLOGY FOR ~20 YEARS AND THE E. RICHARD STIEHM PROFESSOR OF PEDIATRIC IMMUNOLOGY AT UCLA AND DIVISION CHIEF. I AM A T-CELL IMMUNOLOGIST AND HAVE RUN A RESEARCH LAB AT UCLA AND STANFORD FUNDED WITH OVER $15M FROM THE NIH, NSF, FOUNDATIONS, AND PHILANTHROPY. I HAVE PUBLISHED OVER 200 PAPERS, H-INDEX 58, AND HAVE DEEP EXPERTISE BASIC AND CLINICAL IMMUNOLOGY. I HAVE DEVOTED MY CAREER TO TREATING INBORN ERRORS OF IMMUNITY, IN MANY CASES BY REPURPOSING DRUGS THAT ARE PRECISELY TARGETED TO A MOLECULAR PATHWAY GONE AWRY. I SOUGHT A MALT1 INHIBITOR AS A TREATMENT FOR CARD11 GOF AFTER TAKING CARE OF A CHILD WITH SEVERE AUTOIMMUNITY AND INFECTIONS DUE TO CARD11 GOF. THE BOARD OF DIRECTORS OF RHEOS APPROACHED ME AFTER THEY WERE DEFUNCT TO FORM RAREFIED, TAKE OVER THE MALT1 INHIBITOR, AND DEVELOP IT FOR THIS RARE DISEASE. MOTIVATED BY MY FRUITFUL ACADEMIC CAREER IN INBORN ERRORS OF IMMUNITY, I AM NOW SEEKING SBIR PHASE 1 FUNDS TO DEVELOP IN VITRO DATA TO SUPPORT THE COMMERCIAL POTENTIAL FOR MALT1 INHIBITORS AS A TREATMENT FOR CARD11 GOF. OUR MALT1 INHIBITOR DRUG HAS AN APPROVED IND (FOR AUTOIMMUNE DISEASES) AND HAS ALREADY UNDERGONE SIGNIFICANT PRECLINICAL DEVELOPMENT: IT HAS EXCELLENT ORAL BIOAVAILABILITY, HIGH SAFETY MARGINS IN TOXICOLOGY STUDIES IN DOGS AND RATS, AND EXCELLENT IN VITRO SAFETY DATA. A PHASE 1 CLINICAL TRIAL TO ESTABLISH SAFETY IN HEALTHY HUMANS (NOT OUR GOAL HERE) BEGINS IN MARCH 2025. RHEOS HAD FOCUSED ON AUTOIMMUNITY AND DID NOT TEST THEIR INHIBITOR IN CARD11 GOF DISEASES. WE NEED PRECLINICAL DATA TO SHOW ITS UTILITY IN CARD11 GOF DISEASES, WHICH IS THE GOAL OF THIS PROPOSAL. THESE STUDIES WILL OFFER MECHANISM OF ACTION DATA NEEDED FOR FDA CONSIDERATIONS. HERE WE WILL CONDUCT TESTS USING CELLS AND CELL LINES FROM BENTA PATIENTS AND HEALTHY CONTROLS. IF SUCCESSFUL, WE WILL THEN MOVE ON TO STUDYING THE DRUG IN MOUSE MODELS OF BENTA DISEASE IN A FUTURE APPLICATION. SUCCESS WOULD PAVE THE WAY FOR FUTURE CLINICAL TRIALS IN CHILDREN SUFFERING WITH THESE DISEASES.

SBIR PHASE I: DEVELOPING 'SAFE' (SMART-ACTIVITY-FOCUSED-ECO) PLANT TERPENOID DERIVED BIOPESTICIDES -THE BROADER/COMMERCIAL IMPACT OF THIS SMALL BUSINESS INNOVATION RESEARCH PHASE I PROJECT ADDRESSES THE URGENT NEED FOR EFFECTIVE AGRICULTURAL PEST CONTROL SOLUTIONS THAT PROTECT HUMAN HEALTH AND ENVIRONMENTAL QUALITY. CONVENTIONAL PESTICIDES LEAVE PERSISTENT RESIDUES IN SOIL, WATER, AND FOOD PRODUCTS, WITH NEARLY TWO-THIRDS OF GLOBAL AGRICULTURAL LANDS CURRENTLY IMPACTED BY AGROCHEMICALS EXCEEDING SAFE LEVELS. THIS PROJECT WILL DEVELOP NATURAL PEST CONTROL PRODUCTS DERIVED FROM PLANT TERPENOIDS THAT PROVIDE EFFECTIVE PEST MANAGEMENT WHILE BREAKING DOWN RAPIDLY IN THE ENVIRONMENT, LEAVING MINIMAL RESIDUES. THESE INNOVATIONS DIRECTLY SERVE THE NATIONAL INTEREST BY SUPPORTING THE TRANSITION TOWARD SUSTAINABLE AGRICULTURE, REDUCING CHEMICAL CONTAMINATION OF FOOD AND WATER SUPPLIES, AND PROTECTING ECOSYSTEM BIODIVERSITY. THE TECHNOLOGY WILL BENEFIT ORGANIC FARMERS, GREENHOUSE VEGETABLE PRODUCERS, AND CONSUMERS SEEKING PESTICIDE-FREE FOOD OPTIONS. BY EXPANDING THE AVAILABILITY OF EFFECTIVE NATURAL PEST CONTROL METHODS, THIS PROJECT SUPPORTS FOOD SECURITY, ENVIRONMENTAL PROTECTION, AND PUBLIC HEALTH OBJECTIVES ALIGNED WITH NATIONAL PRIORITIES FOR SUSTAINABLE AGRICULTURAL INNOVATION. THIS PROJECT ADDRESSES THE HIGH-RISK TECHNICAL CHALLENGE OF IDENTIFYING SYNERGISTIC COMBINATIONS OF MULTIPLE TERPENOID ACTIVE INGREDIENTS WHILE BALANCING ISOLATE AVAILABILITY ECONOMICS, PEST EFFICACY, AND HUMAN SAFETY TO CREATE COMMERCIALLY VIABLE PRODUCTS. THE INNOVATION LIES IN DEVELOPING PRECISE MULTI-COMPONENT FORMULATIONS WHERE TERPENOIDS ARE COMBINED IN SPECIFIC RATIOS WITH NATURAL EMULSIFIERS AND SURFACTANTS. THESE FORMULATIONS WILL ACHIEVE CONTROLLED DELIVERY AND ENHANCED MORTALITY AGAINST DIFFICULT-TO-CONTROL PESTS SUCH AS SPIDER MITES, WHILE MAINTAINING RAPID ENVIRONMENTAL DEGRADATION AND MINIMAL OFF-TARGET TOXICITY. TESTING COMBINATORIAL SYNERGY PRESENTS SIGNIFICANT COMPLEXITY DUE TO THE VAST ARRAY OF POSSIBLE TERPENOID COMBINATIONS AND CONCENTRATION RATIOS THAT MUST BE SYSTEMATICALLY EVALUATED AGAINST MULTIPLE PEST SPECIES. THE RESEARCH SCOPE INCLUDES EXPANDED PHYTOTOXICITY RESEARCH ACROSS DIVERSE CROPS, MORTALITY ASSAYS AGAINST ADDITIONAL INSECT PESTS AND FUNGAL PATHOGENS, ANTIBACTERIAL ACTIVITY ASSESSMENT, AND RESIDUE TRACKING IN WHOLE PLANT TISSUES ACROSS FULL CROP CYCLES. THIS PROJECT WILL EMPLOY GREENHOUSE BIOASSAYS, ANALYTICAL CHEMISTRY METHODS FOR RESIDUE QUANTIFICATION, FORMULATION STABILITY TESTING, AND PARTICLE SIZE OPTIMIZATION TECHNIQUES. THE INTELLECTUAL CONTRIBUTION WILL ESTABLISH FOUNDATIONAL KNOWLEDGE FOR DEVELOPING FUTURE TERPENOID COMBINATIONS WITH TARGETED PEST CONTROL CAPABILITIES AND ENHANCED SAFETY PROFILES THAT REDUCE OCCUPATIONAL EXPOSURE FOR PRODUCERS AND RESIDUE INTAKE FOR CONSUMERS. THE INTERNAL DATA GENERATED WILL DIRECTLY INFORM THE DEVELOPMENT OF NEW FORMULATIONS AND COMMERCIAL PRODUCTS THAT CAN BE SIMULTANEOUSLY SAFE, EFFECTIVE, AND ECONOMICAL FOR BOTH PRODUCERS AND CONSUMERS WHILE COMPETING WITH CONVENTIONAL SYNTHETIC PESTICIDES. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE PLANNED FOR THIS AWARD.

GRASSHOPPER SPARROW CAPTIVE BREEDING

SBIR PHASE I: MICROBIAL PRODUCTION OF PARAXANTHINE, A CAFFEINE REPLACEMENT

OXYGEN-GUIDED THERAPY FOR OPTIMAL REHABILITATION FOR PERIPHERAL ARTERY DISEASE - SUMMARY THIS WORKFORCE DIVERSITY SUPPLEMENT PROPOSAL SEEKS TO CREATE AN OPPORTUNITY TO ENHANCE THE RESOURCES, ENVIRONMENT, AND CULTURE OF INFRARED RX IN OUR ORGANIZATION'S EFFORTS TO ADVANCE TECHNOLOGY TO SERVE PATIENTS SUFFERING FROM DISABLING PERIPHERAL ARTERY DISEASE. AT THE SAME TIME, IT REFLECTS OUR COMMITMENT TO PROMOTING A DIVERSE WORKFORCE AND TO FURTHER CAREER DEVELOPMENT FOR UNDERREPRESENTED GROUPS IN SCIENCE AND BUSINESS. IN THIS PROPOSAL, WE HAVE CREATED A ROLE WITHIN THE ORGANIZATION FOR THE CANDIDATE TO EXPAND KNOWLEDGE, ACQUIRE SKILLS, AND SHAPE ATTITUDES IN SCIENCE, MEDICINE, AND ENTREPRENEURSHIP. MEANWHILE, THIS ROLE WILL ADD VALUE TO OUR COMPANY, THE TECHNOLOGY WE DEVELOP, AND THE PATIENTS WE SEEK TO SERVE.

DISEASE NATURAL HISTORY DATABASE DEVELOPMENT

HIGHLY MULTIPLEXED ANALYSIS OF SOLID TUMORS AND LIQUID TISSUES BY CYCLIC IMMUNOFLUORESCENCE

ULTRAFAST THZ SWITCHES USING PERFECTLY ABSORBING METAL FREE METASURFACES

DEMONSTRATE SMALL-SCALE VESSEL MONITORING TECHNOLOGY AS A MODEL FOR INTEGRATING REAL-TIME SURVEILLANCE INTO COMMUNITY-BASED FISHERIES MANAGEMENT.

SBIR PHASE I: DEVELOPMENT OF SOLUBLE ANALYTE AMPLIFICATION FOR PBP2A DETECTION

SBIR PHASE I: BRAINSTEM

THE NASA INNOVATIVE ADVANCED CONCEPTS (NIAC) PROGRAM FOCUSES ON EARLY-STAGE FEASIBILITY STUDIES OF VISIONARY CONCEPTS THAT ADDRESS NATIONAL GOVERNMENT AND COMMERCIAL AEROSPACE GOALS. CONCEPTS ARE SOLICITED FROM ANY FIELD OF STUDY THAT OFFERS A RADICA

PREVENTING VASCULAR COMPLICATIONS IN TYPE 1 DIABETES: MUSCLE METABOLIC MONITORING

SBIR PHASE I: SUSTAINABLE RARE EARTH ELEMENT RECYCLING FROM NEODYMIUM MAGNETS

SBIR PHASE I: DYNAMIC INFRARED-IMAGING OF SKIN CANCER (DISC)

HANDHELD OPTICAL SPECTROMETER FOR REAL-TIME CHARACTERIZATION OF DIGESTIBLE PROTEIN IN SOYBEANS

A SURVEY OF CHIMPANZEES IN SOUTHWEST NIGERIA

REAP RENEWABLE ENERGY SYSTEM (RES) GRANT UNRESTRICTED AMOUNT

HAWKSBILL SEA TURTLE MANAGEMENT

A PRIDE CAMPAIGN FOR TIGER CONSERVATION AT NAM ET-PHOU LOUEY NATIONAL PROTECTED AREA LAOS

PURPOSE: TO SUPPORT THE PREMIERE AND RECORDING OF A NEW WORK BY COMPOSER MARK BULLER AND LIBRETTIST LEAH LAX.

PURPOSE: TO SUPPORT A CONCERT SERIES PAIRING PERFORMANCES OF BEETHOVENS LATE STRING QUARTETS WITH PREMIERES OF NEW WORKS OR POEMS WITH RELATED EDUCATIONAL ACTIVITIES.

TO SUPPORT A CONCERT SERIES PAIRING PERFORMANCES OF BEETHOVENS LATE STRING QUARTETS WITH PREMIERES OF NEW WORKS OR POEMS WITH RELATED EDUCATIONAL ACTIVITIES.

TO SUPPORT A TOUR TO MIDWESTERN STATES.

TO SUPPORT THE RECORDING OF WORKS BY AFRICAN-AMERICAN COMPOSER MARGARET BONDS AND SELECTED COMMISSIONS BY CONTEMPORARY COMPOSERS.

TO SUPPORT A RECORDING PROJECT OF MUSIC FOR CHORUS AND GUITARS.

TO SUPPORT A CONTEMPORARY CHORAL MUSIC FESTIVAL.

TO SUPPORT RECORDINGS OF CHORAL WORKS BY COMPOSERS MARK ADAMO, JOHN CORIGLIANO, AND ROBERT KYR.

TO SUPPORT A TOUR OF "CONSIDERING MATTHEW SHEPARD" BY CRAIG HELLA JOHNSON WITH RELATED EDUCATIONAL ACTIVITIES.

TO SUPPORT A TOUR OF CHORAL CONCERTS AND EDUCATIONAL ACTIVITIES.

TO SUPPORT A TOUR OF CHORAL MUSIC CONCERTS.

TO SUPPORT A COMPACT DISC RECORDING OF A NEW A CAPPELLA CHORAL CYCLE FOR CHAMBER CHOIR BY COMPOSER ERIC WHITACRE.

TO SUPPORT THE RECORDING OF AFRICAN AMERICAN SPIRITUALS.

TO SUPPORT A TOUR OF CHORAL MUSIC PERFORMANCES AS WELL AS RADIO AND ONLINE BROADCASTS.

TO SUPPORT AMERICAN FOLK SONGS, A RECORDING OF CHORAL MUSIC.

THIS GRANT SUPPORTS THE COSTS INCURRED TO IMPLEMENT MEASURES TO RESPOND TO THE NOVEL CORONAVIRUS 2019 (COVID-19), WHICH MAY INCLUDE WORKPLACE SAFETY, MARKET PIVOTS, RETROFITTING FACILITIES, TRANSPORTATION, WORKER HOUSING, AND MEDICAL EXPENSES. IT PROVIDES NEEDED RELIEF TO THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS FOR THEIR COSTS INCURRED BETWEEN JANUARY 27, 2020, THE DATE UPON WHICH THE PUBLIC HEALTH EMERGENCY WAS DECLARED BY THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE (HHS) UNDER SECTION 319 OF THE PUBLIC HEALTH SERVICE ACT, AND DECEMBER 31, 2021. BENEFICIARIES INCLUDE THE EMPLOYEES OF THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS.

TO HOST CAPACITY BUILDING SESSIONS FOR KEY STAKEHOLDERS IN ROMANIA, ACROSS THE COUNTRY, IN NINE KEY GEOGRAPHICAL AREAS

THE PURPOSE OF THIS AWARD IS TO SUPPORT THE PROJECT "ACCESSIBLE NAVIGATION TO A TRANSPARENT EMPLOYMENT PROGRAM"

THIS IS AN AWARD IN THE AMOUNT OF $ 4 889.00 OR 13 415.00 LT TO THE RARE CANCER PATIENTS ADVOCACY GROUP "ROLLD" TO SUPPORT THE CREATION OF A DOCUMENT

DECREASE FROM 50 000. BY 50 000. TO 0.00; REPRESENTS COMPLETE AND FINAL CLOSE-OUT.